Urokinase is a naturally occurring enzyme which was first isolated in urine by Ploug and Kjeldgaard (1957) . They demonstrated its ability to dissolve blood clot. As interest grew in its potential clinical value, reports emerged suggesting that urokinase was helpful in the management of pulmonary embolism (Tow et al., 1967) and, in the dissolving of hyphaema LeGrice, 1963, 1964; Rakusin, 1971) . A number of ophthalmologists have examined its role in the treatment of vitreous haemorrhage. Williamson and Forrester (1972) first reported the favourable effect of urokinase in the eye of a diabetic man. Vitreous haemorrhage had blinded the eye for more than 4 years before treatment. An injection of only 5000 Ploug units of urokinase in 1-5 ml distilled water ultimately restored vision from perception of light to 6/12 (Williamson and Forrester, 1973a, b) . Their series has grown to involve 22 patients, 18 of whom benefited from urokinase (Forrester and Williamson, 1974; . Dugmore and Raichand (1973) described 3 patients all of whom improved after the injection of 25 000 Ploug units of urokinase into their vitreous. Less favourable results were obtained by Cleary et al. (1974) , and Holmes Sellors et al. (1974) , who between them treated 33 patients. Four of these had some improvement in visual acuity, 11 no change, and 2 a deterioration after treatment.
An American study found that urokinase was ineffective in clearing experimentally induced vitreous haemorrhage in 4 speciosa monkeys (Koziol et al., 1975) . These authors also observed that urokinase injected into monkey vitreous in doses of 22 500 CTA units (15 750 Ploug units) or less produced no toxic effects on the eyes; 33 750 CTA units (23 625 Ploug units) produced a localised whitish reaction on the monkey's retinal surface, considered to be a toxic effect. Other fibrinolytic agents used to treat experimental vitreous haemorrhages in rabbits have produced inflammation and necrosis and are known to be antigenic to man (Boyer et al., 1958; Maberley and Chisholm, 1970; Schimek and Steffensen, 1955) .
Intravitreal urokinase has been used as the primary treatment of unresolved vitreous haemorrhage in the Melbourne University Department of Ophthalmology since May 1973. This study considers the outcome of intravitreal urokinase in 27 patients. A total of 34 eyes have been treated with urokinase. Three case histories are outlined, and the post-mortem findings in the eyes of a patient who died 6 days after intravitreal urokinase therapy are described.
Methods
The majority of patients were treated under local anaesthesia and light sedation in a procedure lasting only a few minutes. Preoperatively most patients were given 500 mg acetazolamide, and the pupil of the eye in question was dilated with mydriatics. Sub-rectus stay sutures, under two appropriate rectus muscles, were used to expose either the lower or the upper temporal quadrants of the globe. The pars plana was approached through a scleral incision made parallel to the limbus and guarded by a mattress suture. Urokinase, freshly dissolved in 0-3 ml distilled water, was introduced through a 30-gauge needle under indirect ophthalmoscopic control. Immediately before injection the anterior chamber was entered with a Saunder's needle and a small volume of aqueous released. Usually neither the ora serrata nor the posterior pole was clearly seen. Where practicable the posterior pole was studied for signs of vascular embarrassment. Frequently the eyes became stone hard after as little as 0 3 ml of liquid had been introduced into the vitreous cavity. The mattress suture was tightened before removal of the needle. If the eye continued to feel hard, or showed signs of vascular embarrassment, further aqueous was released from the anterior chamber. Postoperatively topical antibiotic and mydriatic drops were frequently applied. Systemic antibiotic therapy was not given.
Results
Melbourne data to December 1976 are presented in Tables 1 to 5 . The patients' ages ranged from 25 Ten eyes improved objectively and subjectively, 6 of these patients being diabetic (Table 4) . Subjective improvement only was noted in 9 eyes. In 10 the outcome was equivocal. In 3 there was deterioration, with associated dense cataract. Two were lost to follow-up.
There was a very high incidence of hypopyon in this series, 22 cases being encountered (Table 5 ). The usual hypopyon was white, flocculant, virtually painless, and not associated with any chemosis of the conjunctiva (Fig. 1) A diabetic male aged 64 died 6 days postoperatively after postanaesthetic cardiac arrest, having remained deeply comatosed. Dr Hugh Greer provided the following histological report: 'Compared with the controls, the urokinase eye shows red cell debris and macrophages in and on a retinal surface membrane, having the appearance in places of the internal limiting membrane of the retina.' These findings are the only histological changes reported in human material to this date. They would suggest that in the dosage of 25 000 Ploug units human urokinase is not toxic to man's retina (Fig. 2) .
The most serious post-urokinase complication appeared to be cataract, which is in any event amenable to surgery. No prolonged glaucoma or serious corneal disorder was encountered. This lack of corneal problems is particularly noteworthy where urokinase was administered to aphakic eyes. No eyes were lost.
Discussion
The fibrinolytic activity of normal urine was recognised by MacFarlane and Pilling (1947) , and this was subsequently related to its property of activating a b Fig. 2 Sections of retina from a 65-year-old male diabetic following urokinase injection (H and E. x 380): (a) Urokinase eye (see text) (b) Control eye fibrinolysin (Williams, 1951) . These findings were confirnied and extended by the results published by Astrup and Sterndorff (1952) . A complete (direct) activator of plasminogen named urokinase was found to be present in urine. The observation that urokinase accumulated in the urine foam in concentrations approximately 100-fold in potency over that in urine enabled Celander and co-workers to prepare urokinase in large quantities (Celander et al., 1955) . Urokinase is a colourless, water-soluble protein which, when pure, is fairly stable within a large pH and temperature range . It has a molecular weight of 53 000 and, as a proteolytic enzyme, induces lysis of fibrin by activating the transformation of the precursor, plasminogen (profibrinolysin) into active plasmin (fibrinolysin). Plasminogen-free fibrin is not attacked by urokinase, except in unusually high concentrations. It has greater preferential affinity for gel phase plasminogen within a thrombus than for soluble (Machemer, 1976 ) has adopted urokinase as its primary method of treatment for unresolved vitreous haemorrhage. The findings of this study may be contrasted briefly with the reports of Mandelcorn et al. (1976) and Peyman et al. (1976) following vitrectomy. Their visual acuity findings were graded in 'acuity groups'. The standard criterion for significant acuity change, a two-line difference on the Snellen chart, was not followed. When their data are reanalysed by means of this criterion (Table 6 ) a comparison with the data of the urokinase study is of greater significance. The objective improvement following urokinase administration in the Melbourne series, shown in Tables 3  and 4 , was based on this same two-line difference in the Snellen chart, except for cases 2 and 16 (Table 4) .
The 44 cases of vitrectomy classed as improved under this scheme of reanalysis are impressive enough. However, the residue of misery in the failure group, the additional surgery, the glaucoma and corneal problems, not to mention lost eyes, demand some supplementary or alternative treatment. Urokinase deserves an equally careful, prospective evaluation as does vitrectomy in the management of unresolving vitreous haemorrhage. The results of this study suggest that it should be used as a first line of attack in vitreous haemorrhage, vitrectomy being reserved for those patients who fail to respond. The latest work of Forrester et al. (1976) goes some way to account for the mode of action of intravitreal urokinase on vitreous haemorrhage. It still does not explain how haemorrhages of more than 6 months' duration are broken up and cleared. 
